Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1220 results
October 2021
-
Key Release
Novartis erzielt im dritten Quartal solide Ergebnisse – mit starkem Wachstum bei Innovative Medicines. Das Unternehmen kündigt eine strategische Überprüfung von Sandoz an
Ad-hoc-Mitteilung gemäss Art. 53 KR Der Nettoumsatz stieg im dritten Quartal um +5% (kWk¹, +6% USD) Die Division Innovative Medicines wuchs um +7% (kWk, +8% USD)Starke Performance der… -
Key Release
Novartis delivers solid Q3 results, with strong growth in Innovative Medicines. Announces strategic review of Sandoz
Ad hoc announcement pursuant to Art. 53 LR Q3 net sales grew +5% (cc¹, +6% USD) Innovative Medicines grew +7% (cc, +8% USD)Strong performance of key growth drivers: Entresto (+44% cc), Cosentyx… -
Key Release
Novartis réalise de solides résultats au 3e trimestre, avec une forte croissance d’Innovative Medicines, et annonce un examen stratégique de Sandoz
Annonce événementielle selon l’art. 53 RC Chiffre d’affaires net du T3 en progression de +5% (tcc¹, +6% USD)Innovative Medicines: hausse de +7% (tcc, +8% USD)Forte performance des moteurs de… -
Key Release
Novartis top-line results for CANOPY-1 Phase III study support further evaluation of canakinumab in lung cancer
Ad hoc announcement pursuant to Art. 53 LR CANOPY-1 Phase III study did not meet its primary endpoints of overall survival (OS) and progression-free survival (PFS)… -
Media Release
Novartis signs new initial agreement with BioNTech to support fill and finish of the mRNA Pfizer-BioNTech COVID-19 vaccine
At least 24 million doses of the mRNA-based vaccine will be filled in 2022 into vials under sterile conditions at Novartis Technical Operations state-of-the-art facility in Ljubljana, Slovenia New… -
Media Release
Global Heart Hub and Novartis partner to tackle ASCVD, a global health crisis and world’s #1 killer
Invisible Nation is a worldwide network of patient organizations committed to driving a decline in cardiovascular (CV) death by effecting systemic change in atherosclerotic cardiovascular disease (… -
Media Release
Kesimpta® (ofatumumab) data at ECTRIMS highlights preservation of IgG levels and safety experience over extended exposure (~3.5 years) in people living with relapsing multiple sclerosis
ALITHIOS Phase IIIb open-label extension study data based on ~3.5 years of exposure demonstrated that mean immunoglobulin G (IgG) levels in patients treated with Kesimpta remained stable, and there… -
Media Release
Novartis announces FDA and EMA filing acceptances of Beovu® for patients with diabetic macular edema
Regulatory decisions for Beovu (brolucizumab) in diabetic macular edema (DME) are expected in mid-2022 in the US and Europe DME is the leading cause of blindness in adults in developed… -
Media Release
Sandoz completes acquisition of GSK’s cephalosporin business, reinforcing leading global position in antibiotics
Sandoz gains rights to three established brands sold in more than 100 marketsTransaction, including leading global brand Zinnat®, complements Sandoz leadership in generic penicillins with leading… -
Media Release
Novartis to present broad range of portfolio data at ECTRIMS, reinforcing long-standing commitment to people living with multiple sclerosis
Novartis will present 41 abstracts from a wide-ranging multiple sclerosis (MS) portfolio, including new data on Kesimpta® (ofatumumab) and Mayzent® (siponimod)Novartis will be commencing Phase III… -
Media Release
Sandoz Resolves Legacy Federal Government Civil Investigation in the U.S. Regarding Generic Drugs
Company previously disclosed settlement agreement in principle and fully provisioned for this resolution Basel, October 1, 2021 – Sandoz Inc., the U.S. subsidiary of Sandoz,…